Table 4. Association of the genetic variants with the adverse events.

Adverse event (n (%))	Genetic variant	Genotypic frequencies (n (%))		OR (95% CI)	P
		Cases	Controls
Sexual adverse events	ADRB2 16Gly	14 (56%)	21 (25%)	4.58 (1.72–12.20)	0.002*
(25 (22.5%))	SLC6A4 L/S	6 (25%)	44 (53.6%)	0.22 (0.06–0.75)	0.015
Sleepiness (66 (56.7%))	DRD3 9Gly	40 (64.5%)	22 (45.8%)	2.47 (1.00–6.09)	0.050
EPS (40 (36%))	DRD3 9Gly	18 (45%)	44 (62.8%)	0.29 (0.11–0.79)	0.015
Weight gain (40 (36%))	SLC6A4 S/S	1 (2.7%)	17 (24.6%)	0.07 (0.01–0.66)	0.020

Significant findings (^*; P<0.003) and non-significant trends (P<0.05) from the genetic association study after adjusting with the potential confounding variables.

^*P<0.003.